T
Thomas Geiser
Researcher at University of Bern
Publications - 246
Citations - 7477
Thomas Geiser is an academic researcher from University of Bern. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Lung. The author has an hindex of 41, co-authored 229 publications receiving 5987 citations. Previous affiliations of Thomas Geiser include University Hospital of Bern & University Hospital of Basel.
Papers
More filters
Journal ArticleDOI
Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes.
TL;DR: Although the ligand for LESTR could not be identified among a large number of chemotactic cytokines, the high expression in white blood cells and the marked sequence relation to IL-8R1 and IL- 8R2 suggest that LES TR may function in the activation of inflammatory cells.
Journal ArticleDOI
Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort
Dominick E. Shaw,Ana R. Sousa,Stephen J. Fowler,Louise Fleming,Graham Roberts,Graham Roberts,Julie Corfield,Julie Corfield,Ioannis Pandis,Aruna T. Bansal,Elisabeth H. Bel,Charles Auffray,Chris Compton,Hans Bisgaard,Enrica Bucchioni,Massimo Caruso,Pascal Chanez,Barbro Dahlén,Sven-Erik Dahlén,Kerry Dyson,Urs Frey,Thomas Geiser,Maria Gerhardsson de Verdier,David Gibeon,Yike Guo,Simone Hashimoto,Gunilla Hedlin,E. Jeyasingham,P.P. Hekking,Tim Higenbottam,Ildiko Horvath,Alan J. Knox,Norbert Krug,Veit J. Erpenbeck,L. Larsson,Nikos Lazarinis,John G. Matthews,Roelinde Middelveld,Paolo Montuschi,Jacek Musiał,David Myles,Laurie Pahus,Thomas Sandström,Wolfgang Seibold,Florian Singer,Karin Strandberg,Jørgen Vestbo,Nadja Hawwa Vissing,Christophe von Garnier,Ian M. Adcock,Scott Wagers,Anthony Rowe,Peter H. Howarth,Ariane H. Wagener,Ratko Djukanovic,Peter J. Sterk,Kian Fan Chung +56 more
TL;DR: U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment, and is well suited to identify asthma phenotypes using the array of "omic" datasets that are at the core of this systems medicine approach.
Journal ArticleDOI
Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine.
Clemens A. Dahinden,Thomas Geiser,Thomas Brunner,Vinzenz von Tscharner,Daniel Caput,P. Ferrara,Adrian Minty,Marco Baggiolini +7 more
TL;DR: MCP-3 combines the properties of RANTES, a powerful chemoattractant, and MCP-1, a highly effective stimulus of mediator release, and thus has a particularly broad range of activities toward both human basophil and eosinophil leukocytes.
Journal ArticleDOI
Neutrophil activation by monomeric interleukin-8
Krishna Rajarathnam,B.D. Sykes,Cyril M. Kay,Beatrice Dewald,Thomas Geiser,Marco Baggiolini,Ian Clark-Lewis +6 more
TL;DR: An IL-8 analog was chemically synthesized, with the amide nitrogen of leucine-25 methylated to selectivity block formation of hydrogen bonds between monomers and thereby prevent dimerization.
Journal ArticleDOI
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study
Sabina A. Guler,Lukas Ebner,Catherine Aubry-Beigelman,Pierre-Olivier Bridevaux,Martin Brutsche,Christian F. Clarenbach,Christian Garzoni,Thomas Geiser,Alexandra Lenoir,Marco Mancinetti,Bruno Naccini,Sebastian Robert Ott,Lise Piquilloud,Maura Prella,Yok-Ai Que,Paula M. Soccal,Christophe von Garnier,Manuela Funke-Chambour +17 more
TL;DR: In this article, the authors report on initial follow-up 4 months after mild/moderate or severe/critical COVID-19 according to the WHO severity classification, patients after severe or critical CoV-19 had a 20.9 (95% CI 12.4-29.4, p=0.01) lower diffusing capacity (DLCO %-predicted, reduced 6MWD, and exerciseinduced oxygen desaturation.